Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine,

Slides:

Advertisements

Similar presentations

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.

Advertisements

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol.

K30 Case Presentation David Andorsky August 26, 2008.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.

Savage KJ et al. Proc ASH 2015;Abstract 579.

Treatment of early-stage Hodgkin lymphoma

Volume 359, Issue 9323, Pages (June 2002)

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions Chelsea.

Oki Y et al. Proc ASH 2013;Abstract 252.

Response to chemotherapy

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

by James O. Armitage, and Dan L. Longo

by Michele Paessler, and John Choi

Hepatitis C in the rituximab era

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Advances in Biology, Diagnostics, and Treatment of Hodgkin’s Disease

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Protease inhibitors potentiate chemotherapy-induced neutropenia

Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): A Joint.

by Sabah Sallah, and Jim Y. Wan

by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Stage C or not stage C…? by Claire Dearden Blood

Primary testicular lymphoma

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,

Stephen Ansell, MD, PhD Mayo Clinic

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Gordon LI et al. Proc ASH 2010;Abstract 415.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan.

Effects of chemotherapy and radiotherapy on spermatogenesis in humans

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

by Andrew M. Evens, and Lale Kostakoglu

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

by Lapo Alinari, and Kristie A. Blum

Optimizing therapy for nodal marginal zone lymphoma

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Cold agglutinin disease

Presentation transcript:

Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin’s Lymphoma Study Group by H. Tesch, V. Diehl, B. Lathan, D. Hasenclever, M. Sieber, U. Rüffer, A. Engert, J. Franklin, M. Pfreundschuh, K.P. Schalk, G. Schwieder, G. Wulf, G. Dölken, P. Worst, P. Koch, N. Schmitz, U. Bruntsch, C. Tirier, U. Müller, and M. Loeffler Blood Volume 92(12):4560-4567 December 15, 1998 ©1998 by American Society of Hematology

Evolution of dose levels in the BEACOPP scheme. Evolution of dose levels in the BEACOPP scheme. Each dot represents the initial dose level of a patient recruited in the study. Dose escalation in the cohort of patients was performed as described. H. Tesch et al. Blood 1998;92:4560-4567 ©1998 by American Society of Hematology

Comparison of the intended dose levels of cyclophosphamide and etoposide with the actual given levels achieved on average in all cycles. Comparison of the intended dose levels of cyclophosphamide and etoposide with the actual given levels achieved on average in all cycles. Intended dose refers to the initial dose level in the first cycle for each patient and to the intended course duration of 8 × 21 days. Actual dose intensities refer to the total given dose and to the actual duration of the course of all given cycles (last cycle taken as 21 days). Patients separated according to sex and arranged in order of increasing initial dose level. (▴) Given DI of C; (•) given DI of E; (▴) intended DI of C; (•) intended DI of E. H. Tesch et al. Blood 1998;92:4560-4567 ©1998 by American Society of Hematology

Occurence of toxic events in individual patients treated at different dose levels. Occurence of toxic events in individual patients treated at different dose levels. (▪) Toxic response; (○) no toxicity. H. Tesch et al. Blood 1998;92:4560-4567 ©1998 by American Society of Hematology

Estimates of FFTF and SV for patients treated with BEACOPP Estimates of FFTF and SV for patients treated with BEACOPP. FFTF, freedom from treatment failure; SV, overall survival. Estimates of FFTF and SV for patients treated with BEACOPP. FFTF, freedom from treatment failure; SV, overall survival. (□) FF; (◊) 7 failed/60; (□) SV; (+) 6 dead/60. H. Tesch et al. Blood 1998;92:4560-4567 ©1998 by American Society of Hematology